Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATHE Alterity Therapeutics Limited

Trading 02-13 13:41:00 EST

3.48

+0.07

+2.05%

High3.48	Low3.40	Vol6.55K
Open3.40	D1 Closing3.41	Amplitude2.34%
Mkt Cap63.08M	Tradable Cap43.35M	Total Shares18.13M
T/O22.61K	T/O Rate0.05%	Tradable Shares12.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATHE","market":"US","secType":"STK","nameCN":"Alterity Therapeutics Limited","latestPrice":3.48,"timestamp":1771007879882,"preClose":3.41,"halted":0,"volume":6554,"delay":0,"changeRate":0.020527859237536607,"floatShares":12458172,"shares":18125693,"eps":-0.747001,"marketStatus":"Trading","change":0.07,"latestTime":"02-13 13:41:00 EST","open":3.4001,"high":3.48,"low":3.4001,"amount":22612.728772,"amplitude":0.023431,"askPrice":3.52,"askSize":200,"bidPrice":3.37,"bidSize":229,"shortable":3,"etf":0,"ttmEps":-0.747001,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771016400000},"marketStatusCode":2,"adr":0,"adrRate":600,"exchange":"NASDAQ","adjPreClose":3.41,"postHourTrading":{"tag":"盘后","latestPrice":3.5093,"preClose":3.5093,"latestTime":"18:13 EST","volume":92,"amount":313.0442,"timestamp":1770938031363,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.931944},"requestUrl":"/m/hq/s/ATHE","defaultTab":"news","newsList":[{"id":"2607489630","title":"Alterity Therapeutics provides corporate update","url":"https://stock-news.laohu8.com/highlight/detail?id=2607489630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607489630?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:38","pubTimestamp":1769776723,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 Decembe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-provides-corporate-update-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-provides-corporate-update-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ATHE","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2607048316","title":"Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2607048316","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607048316?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:25","pubTimestamp":1769775900,"startTime":"0","endTime":"0","summary":" Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced  Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multip","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/30/3229461/0/en/Alterity-Therapeutics-Appendix-4C-Q2-FY26-Quarterly-Cash-Flow-Report-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU2746668974.SGD","LU2125909759.SGD","LU2237443978.SGD","IE00BKVL7J92.USD","IE00BFXG1179.USD","LU2237443382.USD","LU2237443465.HKD","BK4139","BK4007","LU2125909916.SGD","LU2237443622.USD","LU0267386448.USD","IE00BHPRN162.USD","LU0882574139.USD","LU2746668461.USD","MSA","LU1363072403.SGD","IE00B1BXHZ80.USD","BK4143","LU0971096721.USD","LU2237443549.SGD","IE00BZ1G4Q59.USD","LU0728928796.USD","ATHE","BK4006","CMC","LU0149725797.USD","LU0757428866.USD","LU2211815571.USD","BK4539","LU1923622291.USD","LU0170899867.USD","LU1815336091.USD","LU2237443895.HKD","LENZ"],"gpt_icon":0},{"id":"2605047381","title":"Alterity Therapeutics highlights key 2026 objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2605047381","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605047381?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:36","pubTimestamp":1768999016,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) issued a letter to shareholders, which read in part, “Our goal for 2025 was the successful completion of the Phase 2 p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-highlights-key-2026-objectives-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-highlights-key-2026-objectives-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","ATHE","BK4007","BK4139"],"gpt_icon":0},{"id":"2605910282","title":"Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2605910282","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605910282?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:25","pubTimestamp":1768998300,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, Jan.  21, 2026  (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/21/3222672/0/en/Alterity-Therapeutics-Issues-Shareholder-Letter-Highlighting-2025-Progress-and-Key-Objectives-for-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909759.SGD","BK4539","LU0053671581.USD","LU1815336091.USD","MSA","LU2211815571.USD","PRGS","LU1923622291.USD","BK4097","ATHE","LU0757428866.USD","LU2065732104.USD","BK4139","LU0728928796.USD","BK4143","BK4007","LU2125909916.SGD","LENZ"],"gpt_icon":0},{"id":"2585154783","title":"Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler","url":"https://stock-news.laohu8.com/highlight/detail?id=2585154783","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585154783?lang=en_us&edition=fundamental","pubTime":"2025-11-21 03:05","pubTimestamp":1763665526,"startTime":"0","endTime":"0","summary":"In an exclusive interview, Alterity Therapeutics’ (ATHE) CEO David Stamler met with The Fly to discuss the company, the biotech industry, ongoing t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/meet-alterity-therapeutics-fly-exclusive-interview-with-ceo-david-stamler-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/meet-alterity-therapeutics-fly-exclusive-interview-with-ceo-david-stamler-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHE","BK4139","LENZ","BK4539","BK4007"],"gpt_icon":0},{"id":"2582376169","title":"Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376169","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376169?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:25","pubTimestamp":1762950300,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, Nov.  12, 2025  (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186109/0/en/Alterity-Therapeutics-to-Present-at-the-Bell-Potter-Healthcare-Virtual-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4581","LU0029874061.USD","LU0757428866.USD","BK4139","LABU","XLV","LU1815336091.USD","LU2125909759.SGD","BK4143","LU0128526141.USD","ATHE","LU0053671581.USD","XBI","BK4539","BK4007","LU1923622291.USD","LU0728928796.USD","LU2125909916.SGD","LU2211815571.USD","BK4137","EXT","BK4585","HCSG","MSA","BK4588"],"gpt_icon":0},{"id":"2582879803","title":"Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879803","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879803?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:25","pubTimestamp":1762777500,"startTime":"0","endTime":"0","summary":"– Data highlights symptom stability and enhanced efficacy signals in higher dose group – – Analysis offers valuable insights to guide ongoing development and planning of Phase 3 – MELBOURNE, Australia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184418/0/en/Alterity-Therapeutics-Presents-Promising-Impact-of-ATH434-on-Orthostatic-Hypotension-and-Disease-Progression-in-MSA-at-the-36th-International-Symposium-on-the-Autonomic-Nervous-Sys.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","BK4143","BK4539","LU0053671581.USD","LU2125909916.SGD","ATHE","LU1923622291.USD","LU2211815571.USD","LU2125909759.SGD","MSA","LU0728928796.USD","LENZ","LU1815336091.USD","AAS","BK4139","BK4007"],"gpt_icon":0},{"id":"2574152319","title":"Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2574152319","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574152319?lang=en_us&edition=fundamental","pubTime":"2025-10-09 20:19","pubTimestamp":1760012380,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  said Thursday that data from a 77-patient phase 2 clinical trial of its drug ATH434 for the potential treatment of multiple system atrophy slowed disease progression.Chief Executive David Stamler said the ongoing double-blind trial showed a stabilization of orthostatic hypotension, a symptom of multiple system atrophy, at 52 weeks.According to the analysis, ATH434 resulted in a clinically significant reduction in disease severity in comparison with a placebo at both dose levels, with a 48% relative treatment effect at the 50mg dose and a 30% relative treatment effect at the 75mg dose at 52 weeks, the company said.\"This new analysis continues to support our belief that ATH434 has great potential to treat this devastating disease,\" Stamler said.Multiple system atrophy is a disorder similar to Parkinson's disease.ATH434 has already been granted fast-track designation by the US Food and Drug Administration and orphan drug designation by both the FDA and the European ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ATHE"],"gpt_icon":0},{"id":"2574151683","title":"Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2574151683","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574151683?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:25","pubTimestamp":1760009100,"startTime":"0","endTime":"0","summary":"– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/09/3164032/0/en/Alterity-Therapeutics-Presents-Positive-Data-from-ATH434-Phase-2-Trial-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909759.SGD","CSF","BK4539","LU0053671581.USD","LU1815336091.USD","MSA","LU2211815571.USD","LU1923622291.USD","ATHE","LU0757428866.USD","BK4139","LU0728928796.USD","BK4143","BK4007","LU2125909916.SGD","LENZ"],"gpt_icon":0},{"id":"2572514814","title":"Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2572514814","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572514814?lang=en_us&edition=fundamental","pubTime":"2025-10-02 19:35","pubTimestamp":1759404900,"startTime":"0","endTime":"0","summary":"– Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations – MELBOURNE, Australia and SAN FRANCISCO, Oct.  02, 2025  (GLOBE NEWSWIRE) -- Alterit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/02/3160282/0/en/Alterity-Therapeutics-to-Deliver-Multiple-Presentations-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","LENZ","BK4143","LU2125909759.SGD","LU2211815571.USD","LU1923622291.USD","ATHE","LU0053671581.USD","LU0757428866.USD","BK4139","MSA","BK4539","BK4007","LU0728928796.USD","LU2125909916.SGD"],"gpt_icon":0},{"id":"2567119312","title":"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2567119312","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567119312?lang=en_us&edition=fundamental","pubTime":"2025-09-15 19:25","pubTimestamp":1757935500,"startTime":"0","endTime":"0","summary":"ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg dosesMELBOURNE, Australia and SAN FRANCISCO, Sept.  15, 2025  (GLOBE NEW","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/15/3149876/0/en/Alterity-Therapeutics-Presents-ATH434-201-Phase-2-Data-at-the-American-Neurological-Association-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4107","BK4007","MSA","LU1923622291.USD","LU2125909916.SGD","AFG","LU1815336091.USD","LU2211815571.USD","BK4539","LU0757428866.USD","LU0728928796.USD","BK4143","LU0053671581.USD","LU2125909759.SGD","ATHE","BK4117"],"gpt_icon":0},{"id":"2564480439","title":"Alterity Therapeutics to Present at the Biotech Showcase","url":"https://stock-news.laohu8.com/highlight/detail?id=2564480439","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564480439?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:25","pubTimestamp":1756812300,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, Sept.  02, 2025  (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/02/3142531/0/en/Alterity-Therapeutics-to-Present-at-the-Biotech-Showcase.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909759.SGD","LU0757428866.USD","LU1923622291.USD","BK4143","LENZ","LU0053671581.USD","LU2125909916.SGD","LU1815336091.USD","BK4139","ATHE","LU0728928796.USD","LU2211815571.USD","MSA","BK4539","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alteritytherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1001},{"period":"1month","weight":0.0321},{"period":"3month","weight":-0.0861},{"period":"6month","weight":-0.3316},{"period":"1year","weight":-0.1645},{"period":"ytd","weight":0.1394}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.094427},{"month":2,"riseRate":0.375,"avgChangeRate":-0.063542},{"month":3,"riseRate":0.391304,"avgChangeRate":0.001572},{"month":4,"riseRate":0.521739,"avgChangeRate":-0.018138},{"month":5,"riseRate":0.391304,"avgChangeRate":-0.040446},{"month":6,"riseRate":0.304348,"avgChangeRate":0.020916},{"month":7,"riseRate":0.565217,"avgChangeRate":0.095701},{"month":8,"riseRate":0.565217,"avgChangeRate":0.06488},{"month":9,"riseRate":0.26087,"avgChangeRate":-0.044502},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.065816},{"month":11,"riseRate":0.416667,"avgChangeRate":-0.021378},{"month":12,"riseRate":0.291667,"avgChangeRate":0.02698}],"exchange":"NASDAQ","name":"Alterity Therapeutics Limited","nameEN":"Alterity Therapeutics Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alterity Therapeutics Limited(ATHE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alterity Therapeutics Limited,ATHE,Alterity Therapeutics Limited股票,Alterity Therapeutics Limited股票老虎,Alterity Therapeutics Limited股票老虎国际,Alterity Therapeutics Limited行情,Alterity Therapeutics Limited股票行情,Alterity Therapeutics Limited股价,Alterity Therapeutics Limited股市,Alterity Therapeutics Limited股票价格,Alterity Therapeutics Limited股票交易,Alterity Therapeutics Limited股票购买,Alterity Therapeutics Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alterity Therapeutics Limited(ATHE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}